What is Peptris?
Peptris operates at the intersection of artificial intelligence and life sciences, specializing in the generation of novel molecules and the prediction of critical parameters for drug development. The company's platform is engineered to streamline the discovery process, facilitating both drug repurposing and the rescue of stalled therapeutic programs. With a proven track record that includes the successful licensing of its first program targeting Duchenne Muscular Dystrophy, Peptris has demonstrated its ability to transition from computational modeling to tangible clinical development. Its market position is defined by its agility and its focus on high-impact therapeutic areas, making it a standout entity in the competitive landscape of AI-led drug discovery.
How much funding has Peptris raised?
Peptris has raised a total of $8.7M across 2 funding rounds:
Other Financing Round
$1M
Series A
$7.7M
Other Financing Round (2023): $1M with participation from Speciale Invest
Series A (2026): $7.7M led by Tenacity Ventures, Speciale Invest, BYT Capital, and Indian Angel Network
Key Investors in Peptris
Speciale Invest
Speciale Invest is a venture capital firm that supports visionary founders in the DeepTech and frontier technology sectors, focusing on early-stage investments in AI-led software and human longevity.
Tenacity Ventures
Tenacity Ventures is an early-growth investment firm targeting Indian entrepreneurs in the software, biotechnology, and life sciences sectors with a focus on high-margin, breakthrough technologies.
BYT Capital
BYT Capital accelerates groundbreaking ventures in advanced technology, specifically targeting science-led companies in the biotech and artificial intelligence sectors from pre-seed to Series A.
What's next for Peptris?
With this recent capital injection, Peptris is well-positioned to scale its operations and expand its pipeline of therapeutic candidates. The company's strategic roadmap focuses on deepening its AI capabilities to further reduce the time and cost associated with pre-clinical trials. As it moves toward more advanced clinical development stages, the firm will likely prioritize the expansion of its intellectual property portfolio and the formation of additional high-value licensing partnerships. By maintaining its focus on high-margin, science-led innovation, Peptris is poised to capitalize on the growing demand for efficient, technology-enabled drug discovery solutions, ultimately aiming for long-term scalability and industry-wide impact.
See full Peptris company page
